<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01187992</url>
  </required_header>
  <id_info>
    <org_study_id>SFN/02/03/AL</org_study_id>
    <nct_id>NCT01187992</nct_id>
  </id_info>
  <brief_title>Full-dose Atorvastatin After Acute Coronary Syndrome (ACS) in Non-revascularisable Coronary Artery Disease</brief_title>
  <acronym>APRIRE</acronym>
  <official_title>Full-dose Atorvastatin Versus Conventional Medical Therapy After Non-ST-elevation Acute Myocardial Infarction in Patients With Advanced Non-revascularisable Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Filippo Neri General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Associazione Nazionale Medici Cardiologi Ospedalieri</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>San Filippo Neri General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to test the hypothesis that the addition of full-dose atorvastatin
      (80 mg/day) to conventional medical treatment could reduce ischaemic recurrences after
      non-ST-elevation acute myocardial infarction (NSTE-AMI) in patients with severe and diffuse
      coronary artery disease (CAD) not amenable to any form of mechanical revascularisation.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis showed significant effect in favour of full-dose atorvastatin.
  </why_stopped>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>12 months</time_frame>
    <description>The primary end point of the study was prospectively defined as the combination of cardiovascular death, non-fatal acute myocardial re-infarction (re-AMI) and disabling non-fatal stroke.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal acute myocardial re-infarction (re-AMI)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disabling non-fatal stroke</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New-onset heart failure</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">290</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Full-dose atorovastatin (80 mg/d)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For patients randomised to this arm, atorvastatin in the fixed dose of 80 mg/ day was started immediately after randomisation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional medical treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>For patients randomised to this arm, adherence to the National Cholesterol Education Program, Adult Treatment Panel III guidelines was required. In particular, in these patients,atorvastatin was started at the initial dosage of 20 mg/day immediately after randomisation. Subsequently, atorvastatin dosage was titrated in order to attain low-density lipoprotein cholesterol (LDL-C) levels &lt;100 mg/dL (2.5 mmol/L).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>80 mg/day</description>
    <arm_group_label>Full-dose atorovastatin (80 mg/d)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non-ST-segment elevation acute myocardial infarction.

          -  coronary angiography within 48 hours from admission.

          -  angiographic evidence of severe and diffuse coronary artery disease,not amenable to
             conventional direct revascularisation techniques by coronary artery bypass graft
             (CABG) or percutaneous coronary intervention (PCI).

        Exclusion Criteria:

          -  ST-segment elevation acute myocardial infarction,

          -  clinical history of heart failure

          -  left ventricular ejection fraction &lt;35%,

          -  any form of severe valvular dysfunction,

          -  previous implantation or indication to implant a cardioverter-defibrillator during the
             index admission,

          -  any increase in liver enzymes,

          -  history of any liver or muscle disease,

          -  renal failure with serum creatinine &gt;2.5 mg/dL (221 mmol/L),

          -  need for continued use of intravenous medications to relieve anginal symptoms,

          -  presence of any major comorbidity with life expectancy &lt;24 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Furio Colivicchi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Quality Mangement Unit, San Filippo Neri Hospital, Rome, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Filippo Neri General Hospital</name>
      <address>
        <city>Rome</city>
        <zip>I-00135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Colivicchi F, Tubaro M, Mocini D, Genovesi Ebert A, Strano S, Melina G, Uguccioni M, Santini M. Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease. Curr Med Res Opin. 2010 Jun;26(6):1277-84. doi: 10.1185/03007991003751496.</citation>
    <PMID>20367555</PMID>
  </results_reference>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2010</study_first_submitted>
  <study_first_submitted_qc>August 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2010</study_first_posted>
  <last_update_submitted>August 24, 2010</last_update_submitted>
  <last_update_submitted_qc>August 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Furio Colivicchi, MD, FESC</name_title>
    <organization>Clinical Quality management Unit, Cardiovascular Department, San Filippo Neri Hospital, Rome Italy</organization>
  </responsible_party>
  <keyword>Atorvastatin</keyword>
  <keyword>Acute coronary syndrome</keyword>
  <keyword>Advanced coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

